A novel fixed dose combination in a single tablet for TB prophylaxis in HIV
Cipla has received an approval for its product Q-TIB from World Health Organisation (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally. Q-TIB will help prevent tuberculosis infection in people living with HIV.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
